A team bound by a shared vision
MagIA diagnostics innovative diagnostic technology is the culmination of a remarkable 15-year collaboration among several research institutes based in Grenoble, France. Our innovation, protected by multiple patents, employs magnetic interactions at the submillimeter scale for pathogen detection. The developed immunoassay has been extensively studied in various theses, unveiling its versatility across various biological parameters, its substantial clinical potential, and its suitability for industrial applications. The team was mentored by a local incubator, the SATT Linksium Grenoble. During this time, the MagIA technology was improved with the help of medical doctors, diagnostics experts and pharmaceutical companies in order to create practical solutions for our future customers.
In 2017, after two years of incubation and mentoring, the legal entity MagIA diagnostics was born. From the very beginning, the entrepreneurial spirit of the team was led by the ambition to make a deeptech breakthrough available to as many people as possible and have a major impact on the most serious public health issues.
After several interviews of KOL, end-users, the choice has been made to first focus on developing a combined approach for HIV and Viral Hepatitis screening. This vision has been made a reality through the generous support of private investors, including doctors and medtech entrepreneurs who were captivated by our technology from an early stage. Over three successful fundraising rounds, their backing has allowed us to:
- Advance our research and development to transform our technology into a user-friendly solution.
- Achieve complete industrialization, providing us with the necessary capacity for a successful market launch.
- Implement a robust Quality Management System, culminating in our recent ISO13485 certification.
- Enter the crucial phase of clinical validation.
These remarkable achievements would not have been feasible without the dedication and diversity of our exceptional team. Since 2017, MagIA Diagnostics has created over 20 jobs. We strongly believe in fostering a collaborative, stimulating, and friendly work environment, ensuring that every team member can progress alongside our project.
We take immense pride in contributing to opportunities within our region and are constantly on the lookout for new collaborators as we continue to grow rapidly. Explore our current job openings on Linkedin or send us your job application here to be a part of our exciting journey. Together, we are making a difference in the world of diagnostics and public health.
Founders
A team working together since the beginning
Paul
KAUFFMANN
President & Business Development
Paul, our CEO, is in charge of business development. After a PhD in magnetism applied to biomanipulation in Grenoble, Paul evolved internationally in the US and in France in two start-up companies mainly focused on cell manipulation and innovative high throughput screening solutions. In December 2014, he returned to Grenoble to join our group and launch the start-up.
Cédric
BRUIX
Finance & Operations
After graduating from ESSEC Business School (Paris), Cédric worked at Banque Paribas in France and in New York in structured finance transactions. In 1999, he joined the European private equity investor, Argos Soditic, where he spent 17 years (inc.10 years as partner) leading investments in France and in Switzerland. Cédric joined MagIA diagnostics in 2017 as CFO.
Sarah
DELSHADI
Research & Development
Sarah, the biologist of the team was trained in in vitro diagnostics. In 2013, she developed a biomolecular test for infectious diseases at the Institut Pasteur (Madagascar). During her PhD (IAB and G2ELab), she developed the protocol which is now used in the MagIA immunoassay. Since 2017, she is in charge of the Research & Development (RD) efforts and Regulatory Affairs (RA).
Mario
FRATZL
Industrialization
Mario joined the MagIA diagnostics team in spring 2015 as a master student. He is a mechanical and process engineer by training and possesses strong skills in microfluidics. During his PhD, he worked on the micromagnetic structures as well as the microfluidic cartridge concept. Since 2018, he is in charge of the industrialization and production of the cartridge at MagIA diagnostics.
Paul
KAUFFMANN
President & Business Development
Paul, our CEO, is in charge of business development. After a PhD in magnetism applied to biomanipulation in Grenoble, Paul evolved internationally in the US and in France in two start-up companies mainly focused on cell manipulation and innovative high throughput screening solutions. In December 2014, he returned to Grenoble to join our group and launch the start-up.
Cédric
BRUIX
Finance & Operations
After graduating from ESSEC Business School (Paris), Cédric worked at Banque Paribas in France and in New York in structured finance transactions. In 1999, he joined the European private equity investor, Argos Soditic, where he spent 17 years (inc.10 years as partner) leading investments in France and in Switzerland. Cédric joined MagIA diagnostics in 2017 as CFO.
Mario
FRATZL
Industrialization
Mario joined the MagIA diagnostics team in spring 2015 as a master student. He is a mechanical and process engineer by training and possesses strong skills in microfluidics. During his PhD, he worked on the micromagnetic structures as well as the microfluidic cartridge concept. Since 2018, he is in charge of the industrialization and production of the cartridge at MagIA diagnostics.
Sarah
DELSHADI
Research & Development
Sarah, the biologist of the team was trained in in vitro diagnostics. In 2013, she developed a biomolecular test for infectious diseases at the Institut Pasteur (Madagascar). During her PhD (IAB and G2ELab), she developed the protocol which is now used in the MagIA immunoassay. Since 2017, she is in charge of the Research & Development (RD) efforts and Regulatory Affairs (RA).
Board
Philippe
Halfon
Ronald
Delagrange
Thierry
Didier-Vial
Philippe
Pham-Trong
Academic partners
Orphée CUGAT
G2Elab / CNRS
Franz BRUCKERT
LMGP / INP
Patrice MARCHE
IAB / INSERM
Nora DEMPSEY
Institut Néel / CNRS
Orphée CUGAT
G2Elab / CNRS
Franz BRUCKERT
LMGP / INP
Patrice MARCHE
IAB / INSERM
Nora DEMPSEY
Institut Néel / CNRS
Institutional partners
Medical & health care
Health Innovation Clusters
Scientific partners
Public support
Financing
Home
Diagnostics
Life sciences
About us
Contact us
News
Legal Notice
Cookies policy
Log in
Home
Diagnostics
Life sciences
About us
Contact us
News
Legal Notice
Cookies policy
Log in
Home
Diagnostics
Life sciences
About us
Contact us
News
Legal Notice
Cookies policy
Log in
